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1. Introduction 
Functions of the central nervous system (CNS) are mainly performed by neurons and glial 
cells (astrocytes, oligodendrocytes and microglia). Microglia or microcytes have 
macrophage-like immune related functions; oligodendrocytes are the myelinating cells in 
the CNS; and astrocytes have diverse roles in synaptogenesis, neurotransmission, 
myelination and reactive mechanisms to injury. CNS tissue is separated from blood 
circulation by specialized cell barriers, the most extensive being the endothelium of the so-
called blood-brain barrier (BBB).  
Brain cholesterol and lipid homeostasis is largely independent of plasma lipoproteins 
because the BBB restricts the transport of these molecules. In consequence, lipoprotein 
fractions and compositions in the CNS are different from those in the blood, and consist 
mainly of high-density lipoproteins (HDL)-like particles. Glial cells (in particular astrocytes) 
are the main source of cholesterol and HDL-like particles in the CNS [1]. This specialized 
scenario is reflected on the analysis of cerebrospinal fluid (CSF). The CSF contains 
apolipoproteins similar to those of plasma, including apoE, apoA-I and A-II, apoC-I, C-II 
and C-III, apoJ and apoD, but not apoB; apoE and apo A-I are the most abundant. 
Importantly, while HDL-cholesterol and apoA-I in blood influence its levels in the CSF, this 
is not the case for apoE, apoJ and apoD, which are synthetized by glial cells [1-2]. In vitro 
studies have suggested apoA-I expression by brain endothelium and that plasma HDL 
(containing apoA-I) is transcytosed across the BBB [3]. In consequence, the implications of 
plasma lipoprotein metabolism in brain physiology and pathological states have been 
controversial. Nevertheless, many CNS disorders are associated with disturbances of the 
plasma lipoprotein profile and there is increasingly evidence for pathogenic and clinical 
relevance of these alterations.  
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In this chapter we do not pretend to make an exhaustive review on the vast literature related 
to this theme. Rather, we intend to incorporate some relevant studies in a comprehensive 
framework addressed to open new avenues of research. With this purpose, we will mainly 
focus on two frequent and disabling conditions, multiple sclerosis (MS) and Alzheimer 
disease (AD), and discuss the involvement of plasma lipoproteins in brain inflammatory 
and neurodegenerative mechanisms. With this approach we expect that useful insights may 
emerge regarding the contribution of plasma lipoproteins in CNS physiology and 
pathological states. 
2. Multiple sclerosis 
MS is a demyelinating inflammatory and neurodegenerative disease of the CNS with 
heterogeneous pathology (see below) and clinical outcomes. More than 80% of MS patients 
present initially with acute attacks (relapses) of neurological dysfunction (follow by variable 
degree of recovery and periods of “remission”), characterizing the relapsing-remitting 
phenotype (RR-MS). Most of these patients develop a disabling progressive course 
independently of eventual relapses (secondary progressive MS). A small percentage of 
patients (10-15%) presents initially with a progressive disease course (primary progressive 
MS). Patients with clinical isolated syndrome (CIS) have an isolated episode suggestive of 
MS. The investigation of CIS patients is of special theoretical and practical interest because 
of their increased risk to develop the disease. 
A possible involvement of plasma lipoprotein in MS pathogenesis was suggested in 1953 by 
the work of Swank [4]. This author presented evidence for a favorable disease course in 
patients taking a diet poor in animal fat [5]. Sinclair, in 1956, called attention for the 
importance of a deficiency in polyunsaturated fatty acids and remarked similar 
epidemiological aspects of MS and cerebrovascular disease [6]. A landmark work, providing 
a clear potential involvement of plasma lipoproteins in disease was published by Shore et al, 
in 1987 [7]. These authors studied the animal model of MS, experimental autoimmune 
encephalomyelitis (EAE) and concluded that “major changes in apoE-containing lipoproteins are 
undoubtedly significant in the altered immune function in EAE”. Supporting this prediction, it 
was observed higher plasma apoE concentrations in MS patients during relapses in 
comparison to remission states and lower levels in patients under remission in comparison 
to normal controls [8-10]. Studying EAE induction in apoE-deficient female mice, Karussis 
in 2003, found that apoE deficiency might be connected with a defective neuronal repair 
mechanism and enhanced immune reactivity and worse course of the disease [11]. These 
results could indicate that plasma apoE may have an immunosuppressive role in MS [9]. In 
agreement with this concept, our group observed that lower levels of plasma apoE might 
promote immune reactivity in these patients [12]. 
In their work, Shore et al observed higher concentrations of total LDL and HDL 
cholesterol after onset of clinical symptoms. Giubilei et al, in 2002, studied plasma 
lipoproteins and magnetic resonance imaging (MRI) in patients with a first clinical 
episode suggestive of MS (CIS), supporting the findings in EAE [13]. These authors 
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observed high total and HDL-cholesterol in these patients and a significant correlation 
between disease activity (as assessed by MRI) and both total and LDL-cholesterol levels. 
Jamroz-Wisniewska et al found high total cholesterol levels in patients (RR and 
progressive forms) and also higher LDL-cholesterol in RR patients in remission and in 
progressive forms than in healthy subjects [14]. Serum paraoxonase 1 (a HDL associated 
enzyme) activity in relapses was significantly lower in RR patients in comparison to other 
MS groups. An epidemiological survey based on almost 9000 patients with MS found that 
the presence of hypercholesterolemia, among other vascular co-morbidities, increased the 
risk of a more rapid disabling progression of the disease [15]. Recently, Weinstock-
Guttman et al studied the serum lipid profiles in association with clinical disability and 
MRI measures in 492 MS patients [16]. They found that worsening disability was 
associated with higher total and LDL cholesterol, and triglycerides. Higher HDL levels 
were associated with lower probability for the presence of acute inflammatory lesions 
(assessed by MRI). Other authors have found higher HDL-cholesterol (and total blood 
homocysteine) levels in MS patients during a phase of clinical inactivity in comparison to 
normal controls [17]. 
The possible influence of apoE allele polymorphism in MS susceptibility and disease 
severity has been addressed in many studies. Overall, literature does not suggest a role of 
apoE alleles as risk factor of developing MS [18-19]. An association of apoE polymorphism 
with disease severity in MS patients has been more controversial. Using MRI methodology, 
some studies have shown an association between the apoE4 isoform and more severe brain 
tissue destruction in these patients [20-22]. However, an influence of this isoform on the 
clinical course of the disease is not established and the interaction with potential 
confounders should be considered. For example, it was suggested that an influence of apoE 
polymorphism on the clinical course, and even the risk of MS, could particularly exist in 
women [23]. Our group has provided evidence for an influence of cigarette smoking in 
apoE4-carriers, in modulating the clinical severity of RR-MS patients [24]. Some studies have 
suggested an association of apoE4 allele and apoA1 promoter polymorphism with cognitive 
impairment in these patients, which may occur very early in the clinical course of the 
disease [25-26]. 
As mentioned above, MS is a heterogeneous clinical entity. RR-MS has a higher prevalence 
in women (which is increasing) and the course of the disease is in general more disabling in 
men. It is not unreasonable to hypothesize that gender-related and other genetic influences 
could implicate different impacts of lipoprotein metabolism in MS. Few studies have 
analyzed the influence of MS therapies in plasma lipoproteins of these patients. However, 
these studies could provide useful insights on the pathogenic role of this metabolism. Our 
group first suggested that interferon beta therapy changes this metabolism in RR-MS 
patients. In particular, we found that at 12 month of therapy, lower apoA1 and higher apoE 
levels were associated with the presence of relapses and/or progression of the disease [27]. 
Others authors have found that MS therapy is associated with a decrease of plasma total 
cholesterol [28-29]. Overall, the reviewed data strongly support a role of plasma lipoproteins 
metabolism in the pathophysiology of the disease, as discussed below. 
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2.1. Pathophysiological mechanisms 
A major link between plasma lipoproteins and MS concerns the immune system. It is well 
known that immune reactivity interacts with adaptive alterations of lipoprotein metabolism 
[30-31]. Recent reports have showed that distinct metabolic programs are essential for 
survival and functional specialization of different lymphocyte cell populations. For example, 
lipid oxidation is essential for Treg generation while Th1 differentiation and cytokine 
production by differentiated Th1, Th2 and Th17 cells are suppressed by lipids and require 
glucose metabolism [32]. Although the immunopathogenesis of MS lesions (demyelinating 
plaques) is heterogeneous and may differ in different patients, an imbalance favoring a Th1 
effector cell activation is generally accepted [33]. Therefore, it would not be unexpected if an 
abnormal lipid modulation of immune functions could contribute for MS pathogenesis. 
However, a primary role of lymphocytes (T cells and B cells) in mediating CNS injury in this 
disease (at least in all patients) is controversial [32]. Myeloid cells play a pivotal role in the 
regulation of infiltrating lymphocyte cell activities and are involved in myelin breakdown 
and axonal injury [33-34]. Macrophages of M1 phenotype are characterized by high 
production of pro-inflammatory mediators and are crucial in Th1 cell response, while M2 
phenotypes are associated with tissue remodeling/repair and expression of anti-
inflammatory molecules [35]. In MS lesions, myelin phagocytosis by myeloid cells induces a 
foamy appearance. Foamy macrophages are originated from resident myeloid cells 
(microglia) and infiltrating monocytes and are suggested to be of M2-type macrophages and 
to contribute to the resolution of brain inflammation [36-37]. 
Macrophage polarization is modulated by different factors. For example, the M2 
antinflammatory phenotype is induced by HDLs and apoE [35, 38], and fatty acid and 
phospholipid synthesis is essential for phagocytic differentiation of human monocytes [39]. 
ApoE is one ligand for the LDL-receptor-related-protein-1 (LRP1). Quite interesting, LRP1 
mediates the downregulation of microglial inflammatory activity by apoE [40] and is 
essential for phagocytosis of degraded myelin in mice with EAE [41]. Moreover, LRP1 is also 
expressed in neurons and astrocytes and regulates BBB permeability [42]. This scenario is 
consistent with a reduction of inflammatory infiltrates and clinical disability by apoE-
derived peptides in EAE [43] and immunosuppressive and neuroprotective effects of plasma 
apoE in EAE [11] and MS patients [8-10, 12]. 
Among the transcriptional factors regulating macrophage polarization, peroxisome 
proliferator-activated receptor (PPAR) γ is known to promote M2 macrophages [35]. This is 
of potential interest in the context of preliminary evidence implicating PPARs in MS 
pathogenesis and as therapeutic targets for the disease [44-45]. 
In brain, apoE is associated with HDL-like particles, also containing the second major 
apolipoprotein, apoA-I. These apolipoproteins are primarily located on separated 
lipoproteins particles [1]. Although apoE in the brain is predominantly synthetized by glial 
cells, plasma HDL/apoA-I may cross the BBB and influence its levels in the brain [2]. HDL 
effects include an inhibition of cytocine-induced expression of adhesion molecules in 
endothelial cells, which could further depress brain parenchyma immune reactivity [46]. As 
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mentioned, higher levels of plasma HDL were found in CIS and RR-MS and were associated 
with a lower probability in development of acute inflammatory lesions in these patients [13, 
16-17]. Recently, preliminary evidence from our group suggests that higher plasma HDL 
levels are associated with an increased intrathecal IgG synthesis in these patients [47]. 
Because low plasma HDL-cholesterol is associated with a predominance of pro-
inflammatory phenotype of monocyte-derived macrophage [48], these findings suggest an 
immunosuppressive role of HDL in the development of MS lesions. This interpretation is 
further supported by the beneficial therapeutical effects of fingolimod in the disease [49].  
Fingolimod (FTY720) is a structural analog of sphingosine, which down modulates 
sphingosine 1-phosphate (S1P) receptors. S1P is a major component of HDL, including in 
the CNS and induces an anti-inflammatory phenotype in macrophages. SP1 receptors are 
widespread in CNS cells and a defect of sphingolipid and phospholipid metabolism is 
observed early in normal appearing white and grey matter in MS patients. Moreover, S1P is 
reduced in affected white matter and is increased in CSF of these patients [49]. Importantly, 
FTY720 treatment has been shown to have neuroprotective effects independent of 
immunomodulatory mechanisms [50]. These data suggest a protective role of endogenous 
HDL components not only in the genesis of acute inflammatory lesions but also in the 
neurodegenerative process of MS. 
An involvement of oxidative stress in MS, including of lipid peroxidation has recently received 
much support [51]. Newcombe et al, in 1994, demonstrated for the first time the presence of 
oxidized LDL (ox-LDL) and their peroxidative end-products in early and actively 
demyelinating plaques in post-mortem MS brain [36]. They suggested that plasma LDL enters 
(through a damaged BBB) the parenchyma and is oxidatively modified in the lesions. More 
recent data supports an important involvement of oxidative damage including oxidized 
phospholipids in myelin and axon injury in MS [52]. Several studies have also demonstrated 
that measures of oxidative stress and lipid peroxidation are consistently increased in the blood 
of these patients [51]. Our group reported increased levels of serum oxLDL in RR-MS patients 
in remission in comparison to normal controls and higher levels during relapses [53]. These 
findings are consistent with a contribution of plasma ox-LDL in promotion BBB permeability 
and acute inflammatory CNS lesions in the disease. However, increased plasma lipid 
peroxidation or oxidative stress is probably not associated with disability progression in these 
patients [54]. The pathophysiology of acute lesions (MS plaques) and disability progression are 
indeed thought to be mediated by different mechanisms. In fact, it was suggested that low 
oxygen radical formation in peripheral leukocytes may be associated with a increased severity 
of the disease [55]. These findings indicate that the role of oxidative stress in MS is complex. 
An oral formulation of dimethylfumarate (BG-12) activates the Nrf2 antioxidant pathway and 
was recently observed to be of clinical benefit in RR-MS patients, possibly in disease 
progression also [56]. These recent promising results should stimulate future research to clarify 
the involvement of lipid peroxidation in the disease. It should be noted that this involvement 
further supports a role of plasma HDL in disease pathogenesis, as discussed above. Plasma 
HDL-associated α-tocopherol is transcytosed across the BBB and may have antioxidant as well 
as anti-inflammatory effects [3].  
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Ludewig and Laman (2004) remarked the similarities that may exist between the 
atherosclerotic plaque development and MS lesions and suggested: “Systematic comparison 
of these two diseases involving foam cells in chronic lesions may prove fruitful” [57]. As we have 
reviewed, recent research clearly supports this prediction. Moreover, patients with MS 
have several vascular abnormalities and a higher risk for ischemic stroke [58]. In 2003, our 
group first reported a pilot trial suggesting a benefit of statin monotherapy in the 
pathogenesis process (assessed by MRI) and clinical activity of RR-MS patients [59]. These 
beneficial effects were confirmed by Vollmer et al trial in 2004 [60] and in a long-term 
follow-up of our patients [61]. Very recently, beneficial effects of statin monotherapy were 
reported in patients with a first clinical episode (CIS) suggestive of MS [62-63]. A 
synthesis of some shared pathophysiological factors involved in MS and atherosclerosis is 
presented on Table 1. As we will discuss below, the presence of similar mechanisms 
involving plasma lipoprotein metabolism in the pathogenesis of atherosclerosis/ischemic 
and demyelinating lesions may be extensive to other chronic inflammatory and 
neurodegenerative pathologies. 
 
Pathophysiology Comment References 
Lesions 




Total and LDL cholesterol Promotion of lesion formation 
and/or progression
[13-16] 
HDL-Cholesterol Protective of lesion formation 
and/or progression
[13, 16-17, 47] 
ApoA-I Immunosuppressive and 
protective
[26-27] 
ApoE Immunosuppressive and 
protective
[8-10, 12] 
Sphingosine-1-phosphate Modulation of immune 
reactivity and lesion formation
[49-50] 
Oxidative stress and oxLDL Lipid peroxidation in lesion 
formation
[51-53] 
Secretory phospholipase A2 Increased expression [115] 
Immunopathogenesis 
M2-Macrophages Anti-inflammatory, phagocytic 
cells in lesions
[37] 
T-Cells Promoting lesion formation [33] 
Inflammatory cytokines Promoting lesion formation [33] 
Interleukin-10 Protective of lesion formation [116] 
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Pathophysiology Comment References 
Adipocytokines Leptin and Adiponectin 
involvement in immune 
dysfunction
[117-118] 




Statins Pathological and clinical 
benefits
[59, 63] 
PPARs PPAR-gamma agonists 
protective
[45] 
Estrogens Protective of lesion formation 
and/or progression
[119] 
Homocysteine Increased levels associated 
with lesion formation
[17, 58] 
Platelets Increased adhesiveness and 
aggregation 
[58, 120] 
Smoking Promotes lesion formation [121] 
Ischemic events Increased risk associated with 
atherogenesis and MS 
pathogenesis
[58] 
Table 1. Some pathogenic similarities between multiple sclerosis and atherosclerosis. 
3. Alzheimer disease 
Possession of the apoE4 allele is the major genetic risk factor for sporadic late-onset AD [64-
65]. This observation led to a large body of research on cholesterol and lipid metabolism in 
patients and animal models of AD during the last two decades. However, the investigation 
of this metabolism in patients with clinical AD is not sufficient to clarify its role in the 
pathogenesis of the dementia. It is generally accepted that the pathogenic processes in AD 
begin many decades before the appearance of evident symptoms. More recently, a major 
focus of interest has been on longitudinal studies addressing the association between 
lipoprotein profiles and clinical evolution of cognitive normal subjects or patients with mild 
cognitive impairment (MCI). A large percentage of patients with the diagnosis of MCI by 
the 6th decade are known to develop AD later in life. Therefore prospective studies are 
crucial for development of efficient preventive or therapeutic measures. 
Amyloid-β (Aβ) deposition in plaques (AP) (also known senile or neuritic plaques (NP)) and 
neurofibrillary tangles (NFT), characterized by hyperphosphorylated tau protein 
aggregates, are pathologic hallmarks of AD [66-67]. The association between plasma 
lipoprotein profiles and risk of development of clinical manifestations of dementia has been 
controversial. An association between high cholesterol levels in midlife and an increased 
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risk for dementia in old age has been suggested by several publications [68], but it was not 
confirmed by a recent large population study [69]. Instead, this study found that low 
cholesterol levels in late life were predictive of subsequent dementia. Supporting this 
conclusion, another study in elderly individuals found that low HDL-cholesterol and low 
total and Non-HDL cholesterol were associated with higher AD risk [70]. These authors 
suggested a protective effect of late life total cholesterol level on the risk for mild cognitive 
impairment and AD. Low HDL-cholesterol levels were also associated with decline of 
memory in middle-aged adults [71]. Within this framework, decreased plasma apoA-I levels 
have also been found in AD as well as in vascular dementia, and higher apoA-I levels 
associated with decreased risk of dementia [72-73]. Few studies have investigated the 
association of lipid profiles with AD-related pathology. A recent work has found that high 
total cholesterol, LDL-cholesterol and non-HDL-cholesterol levels were associated with risk 
of development of AP, but not NFT [74]. However, as we will discuss below, the genesis of 
pathological hallmarks of AD is not invariably associated with clinical manifestations of 
cognitive impairment and dementia. 
The apoE4 allele is an established risk factor for the development of sporadic AD; it is 
associated with an early age at onset of dementia in an allele dose-dependent manner; and 
with increased Aβ burden. Moreover, in MCI it predicts conversion to AD. In contrast, 
apoE2 allele is associated with delayed age of onset of AD [66]. Recent data have provided 
evidence for an important role of apoE protein levels, independently of the genotype. In one 
study, middle-aged offspring with familial history of AD were found to have lower plasma 
apoE levels when compared with offspring without familial history of AD, independent of 
APOE genotype [75]. In other study, plasma apoE levels were found to be lower in patients 
with AD and decreased with Aβ load [76]. 
Overall the reviewed data strongly support a role of plasma lipoprotein metabolism in the 
pathogenesis of AD, as discussed in more detail below. 
3.1. Pathophysiological mechanisms 
As already mentioned, NP and NFT are the hallmarks of AD pathology. However, these 
aggregates are present in a variable extend in about 30% of cognitively normal elderly 
subjects. In AD, synaptic structural and functional alterations also occur early and are more 
pronounced than in normal ageing individuals. ApoE-containing lipoproteins, mainly 
derived from astrocytes, may influence these pathogenic processes in several ways. 
Cholesterol associated with these lipoproteins is necessary for neurons and to stimulate 
axonal growth and synaptogenesis. Lipidate-apoE contributes for clearing out Aβ from the 
brain, a process mediated by apoE receptors (especially LRP1) present in glial cells, neurons 
and in endothelium of the BBB. Pathways for Aβ clearance also include proteolytic 
degradation and oligomerization in the aggregates of amyloid plaques, mechanisms also 
modulated by apoE. For all these processes the isoform apoE4 (which is in general 
associated with less secreted production of the protein) is less efficient and promotes 
synaptic dysfunction, toxicity of soluble Aβ and NP deposits. Moreover, it is suggested that 
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apoE4 fragments induce mitochondrial dysfunction and neurotoxicity and that cholesterol 
levels may regulate Aβ production [65, 66]. Supporting this important role of apoE for AD 
and the harmful effects of Aβ on cognitive functions, cognitive performance in normal older 
adults was associated with Aβ load (PET), mainly in ε4 carriers [77].  
The above findings do not exclude the contribution of other apolipoproteins for Aβ 
pathology. For example, apoJ and apoD (see below) also modulate Aβ deposition, a 
deficiency of apoA-I promotes cognitive impairment and polymorphisms of all these 
apolipoproteins were associated with risk for AD [1]. Interestingly, increased plasma levels 
of apoJ (clusterin) are not present before the development of AD but are indeed associated 
with the severity and progression of the disease, supporting a neuroprotective role [78]. 
The link between a lipoprotein dysregulation and tau pathology (NFT deposition), in contrast, 
is not well understood. Beyond the involvement of cholesterol and apolipoproteins, AD is 
associated with disturbances of sphingolipids and phospholipid metabolism that may 
contribute for its pathogenesis [67]. Moreover, cognitive impairment and dementia, including 
AD, are frequently associated with markers of systemic and brain inflammatory activity [79], 
vascular atherogenic [80] and white-matter (myelin) pathology [81]. An underlying 
dysregulation of lipoprotein metabolism could be linked to all these pathogenic pathways.  
The scenario briefly described above is clearly consistent with the observations that low 
plasma apoE may be associated with increased risk of AD and correlates with Aβ load, as 
assessed by PET [75-76]. As remarked, the last studies emphasized the importance of total 
apoE levels, independently of the genotype. Supporting this concept, it was recently 
reported in AD mouse models a stimulation of Aβ clearance and cognitive function by 
inducing apoE expression [82]. After apoE-mediated transport through the BBB, plasma Aβ 
transport is accomplished by triglyceride-rich lipoproteins (TRL) rich in apoE, for uptake in 
liver [83]. These findings are also consistent with the risk conferred by low plasma apoE 
levels. Low plasma apoE levels could also promote systemic immune reactivity and 
atherogenic pathology in these patients. 
Although no relation exists between plasma and brain apoE levels, a strong correlation was 
found between HDL-cholesterol and apoA-I in serum and in CSF lipoproteins (which are 
HDL-like particles) [2]. This scenario could contribute to the risk of cognitive impairment 
and AD conferred by low plasma HDL-cholesterol and apoA-I levels [70-73]. On one hand, 
these deficiencies could be linked to an increased systemic inflammatory and oxidative 
status and promotion of atherogenesis. On the other hand, low HDL and apoA-I levels 
would provide less neurotrophic and immunosuppressive abilities to the brain [84]. If high 
total and LDL or non-HDL cholesterol in plasma cannot influence its levels in the brain, how 
could they be associated in some studies with an increased AD risk and Aβ load (NPs)? 
Experimental studies suggest that plasma cholesterol levels do not normally regulate 
production of brain Aβ [85]. One possibility resides in the fact that high non-HDL 
cholesterol in these patients may be associated with low HDL, apoE and apoA-I levels, a 
pro-inflammatory systemic status and increased atherogenic/ischemic pathology. 
Supporting this hypothesis, in animal models, cognitive impairment following high fat diet 
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consumption was associated with brain inflammation [86]. Among other markers of 
inflammation [79], serum levels of adipocytokines have been associated with cognitive 
impairment and progression of AD, as well as atherogenic/ischemic disease [87-88]. 
Metabolic syndrome [89] and insulin resistance and type 2 diabetes [90] are associated not 
only with higher risk of vascular disease but also with risk of dementia, including AD. All 
these conditions may promote the development of dementia also by affecting myelin 
integrity and white-matter connective functions.  
It should be noted that clinical overt cognitive impairment and dementia do not depend 
solely on the severity of neurodegenerative and vascular pathologies. Human brain is 
provided with potential compensatory or plastic mechanism, which may mitigate the 
clinical impact of ageing-associated pathologies [91-92]. This means that in old age, risk 
factors for dementia may not have the same significance they have in previous decades. 
Those factors may include high total and non-HDL cholesterol plasma levels, which may 
have a major impact in promoting atherogenesis/ischemic/inflammatory processes and AD-
related pathology in middle-life, but not in neuroplastic mechanisms increasingly required 
with advancing age. Lower total and LDL cholesterol have indeed been associated with a 
poor prognosis in the ischemic stroke [93] and in elderly individuals, as observed above, this 
profile may increase the risk for overt dementia. Increased body mass index (BMI) in middle 
life appears to be a risk factor for latter development of cognitive decline and AD, but in late 
life the burden of cerebral amyloid and tau is associated with lower BMI in cognitively 
normal and MCI subjects [94-95]. These facts could contribute to the inconsistent results 
regarding the benefits of statins on prevention and treatment of AD, despite in vitro and 
animal studies demonstrating an effect in decreasing Aβ formation [96].  
In Figure 1 are presented some of the suggested implications of lipoproteins in the 
pathogenesis of AD and MS.  
4. Other brain disorders 
Results concerning an association between high serum cholesterol levels and the risk for 
Parkinson disease (PD) have been conflicting. However, this possible association may not exist 
in older subjects (≥55 years). As for AD, low serum total and LDL-cholesterol levels may increase 
the risk of PD with advancing age [97-99]. In this context, it is intriguing that hyperlipidemia 
probably has also a protective role on the neurodegenerative process of amyotrophic lateral 
sclerosis (ALS) [100-101]. PD and ALS also involve inflammatory processes and it has been 
noted some convergence in the mechanisms underlying neurodegeneration in these disorders, in 
AD and MS. [102]. An abnormal brain cholesterol homeostasis may also contribute to the 
pathophysiology of Huntington’s disease [103]. In what concerns PD, and in contrast to AD, an 
involvement of apoE genotypes is not clarified. Several studies reported no influence of apoE4 
allele in the development of PD or in dementia associated with the disease, which is in contrast to 
its established role in AD pathogenesis [104]. However, apoE and LRP1 were found to be 
increased in brain from PD patients, suggesting an involvement in the deposition of α-sinuclein 
aggregates (Lewy bodies) typical of this disease [105]. 
 




Figure 1. Some putative implications of lipoproteins for the pathogenesis of Multiple Sclerosis and 
Alzheimer disease (see text for interpretation). 
As mentioned above, apolipoprotein D in the CNS is normally synthetized by glial cells 
(astrocytes and oligodendrocytes). Although present in the CSF in lower concentrations than 
apoE, A-I and J, some studies have suggested a possible neuroprotective role of apoD in 
neuropathological states [1,106]. ApoD is a member of the lipocalin family of proteins that 
are involved in the transport of small hydrophobic ligands. Among several proposed 
ligands (cholesterol, progesterone, pregnenolone, bilirubin), apoD can bind with high 
affinity arachidonic acid (AA). Inflammatory responses and oxidative stress associated with 
brain insults are known to mobilize AA from membranes. Therefore, apoD could have a 
neuroprotective role by controlling oxidative damage [106-107]. In fact, higher levels of 
apoD have been found in brain or CSF of AD and other neuropathologies [108]. Curiously, 
an increase of apoD has also been reported in plasma and certain brain regions of patients 
with schizophrenia and bipolar disorder. In these conditions, a disturbance of 
phospholipid metabolism has been proposed and apoD could represent a response 
addressed to stabilize membrane AA or bind free AA [106]. The fact that atypical 
antipsychotics such as clozapine up-regulate apoD expression supports neurotrophic effects 
of this protein [106]. It should be noted that other apolipoproteins have been implicated in 
these neuropsychiatric disorders, including apoE, and apoA-I [106, 109-110]. Interestingly, 
as observed for AD and MS, lower serum apoA-I levels were found in schizophrenia [110]. 
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Overall, these data emphasizes the relevance of plasma lipoprotein metabolism in brain 
physiology and the convergence of similar dysfunctions of this metabolism associated with 
several neuropathologies. 
5. Conclusion 
This review has addressed MS and AD as a strategy to explore the potential relevance of 
plasma lipoproteins in CNS inflammatory and neurodegenerative disorders. Despite quite 
different in their demographics, clinical and pathological characteristics, some similarities in 
their inflammatory and neurodegenerative components have been noted previously [102]. 
In MS as in AD, the genesis of brain pathology is thought to begin many years before the 
clinical overt disease. Despite the occurrence of widespread lesions, brain plastic compensatory 
mechanisms may maintain those disorders clinically silent, delay their symptoms or modify 
their clinical evolution. Molecular mechanisms underlying grey and white matter plasticity are 
of outstanding neurobiological and medical importance and are currently poorly understood 
[111]. This review suggests that an involvement of lipoprotein metabolism in brain plasticity 
mechanisms is highly plausible and deserves much future research. 
Clinical signs of MS very rarely first appear in individuals after 60 years of age and sporadic 
AD rarely manifest before that age. However, it is remarkable that a profile of low HDL-
cholesterol, apoE and apoA-I plasma levels and elevated total and non-HDL cholesterol may 
promote the risk or progression of disability in both disorders. As discussed, this profile 
could be associated with both the genesis of lesions in the CNS and the systemic immune-
related or metabolic alterations implicated in their pathophysiology  (Table 1, Figure 1). It is 
to note that disturbances in brain cholesterol transport (that may occur in MS, AD and other 
neuropathologies) can lead to alterations in cholesterol uptake from plasma to brain and 
decrease plasma HDL levels (112). In MS as in AD, this lipoprotein profile may promote 
foam cell plaque formations. In young individuals genetically susceptible to MS, this profile 
may promote the genesis of demyelinating plaques; instead with advanced age, atheroma 
plaques formation prevails, contributing to AD,  in genetically susceptible subjects. 
Supporting this speculation, MS pathogenesis may share many lipoprotein-related and 
inflammatory mechanisms underlying atherogenesis (Table1). In addition, with aging, this 
lipoprotein profile could have a convergent impact for the maintenance of the typical CNS 
lesions occurring in MS and AD. In fact, advanced ageing may be associated with lower 
recruitment of anti-inflammatory and phagocytic macrophages and other blood-derived 
factors to the CNS [113]. This situation, on one hand, favors lower capacity of β-amyloid 
clearance, oligodendrocyte toxicity and myelin lesions, early present in incipient AD. On the 
other hand, it restricts remyelination capacities in MS, which are more accentuated with 
advancing ageing in these patients. The presence of age-related changes in blood circulation 
has recently been noted of possible relevance for MS and AD [114]. These relevant age-
related changes should comprise circulating lipoprotein metabolism. 
Despite the similarities of lipoproteins involvement in these two disorders, including the 
neuroprotective, immunosuppressive and vascular/ischemic protective functions of HDL-
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cholesterol and associated apolipoproteins (Fig. 1), distinctive implications on their 
pathogenesis are expected. In MS, a participation of lymphocyte infiltration is certainly 
important while this is not the case for AD. For example, sphingosine-1-phosphate 
component of HDL could be special relevant for the immune dysfunction and the 
abnormal sphingosine metabolism associated with the genesis of demyelinating plaques 
and neurodegenerative processes in MS. In AD, triglyceride-rich plasma lipoproteins and 
apoE4 isoform are especially relevant in the clearance of Aβ and genesis of amyloid 
plaques. It should be emphasized that MS and AD are pathological and clinical 
heterogeneous diseases. For example, the immunopathogenesis of MS differ among 
patients even with similar clinical profiles and prominent atherosclerosis lesions are 
absent in some patients with AD. Therefore, the contribution of plasma lipoprotein 
metabolism for the pathogenesis of these disorders may be variable and this could explain 
discrepancies among some studies. Future work aimed to clarify the roles of plasma 
lipoproteins in these diseases should address clinical homogeneous patient populations, 
include concomitant pathological and immunological markers and consider potential 
environmental confounders. Ideally, laboratory data should be correlated with 
neuroimaging measures. Finally, MS and AD are clear examples of complex conditions for 
which multiple genetic risk factors for developing and progression are to be expected. 
Selected genetic typing of the study population is therefore convenient, because 
lipoprotein alterations may not have the same significance and the same therapeutical 
implications in different genetic backgrounds.  
In sum, the available reviewed data suggest that plasma lipoproteins metabolism is a 
fruitful “window” to an improved understanding of MS and AD and other neurological 
diseases. Of outstanding interest, plasma lipoproteins may represent useful targets for 
discovering preventive and therapeutical strategies for these common disabling human 
conditions.  
A very recent paper from Dr Lawrence Steinman group at Stanford University highlights 
the importance of lipids in the pathogenesis of MS and the therapeutic potential of lipid-
based strategies for the disease (Science Transl Med 2012; 8 (137); E-pub 2012 6 Jun). 
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